OncoMatch/Clinical Trials/NCT02728388
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
Is NCT02728388 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies aminolevulinic acid for neurofibromatosis 1.
Treatment: aminolevulinic acid — The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Cannot have received: chemotherapy
Previous chemotherapy within 6 weeks of proposed PDT
Cannot have received: tumor therapy
Other concurrent tumor therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Donald G Basel · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02728388 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, tumor therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 30 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify